Vertex Augments Cystic Fibrosis Pipeline with Parion Sciences Deal
By Heather Cartwright & Hardik Mewada
Pharma Deals Review: Vol 2015 Issue 7 (Table of Contents)
Published: 7 Jul-2015
DOI: 10.3833/pdr.v2015.i7.2110 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In order to expand its cystic fibrosis (CF) pipeline beyond CFTR (cystic fibrosis transmembrane conductance regulator) modulators, Vertex Pharmaceuticals has partnered with US-based Parion Sciences for the development and commercialisation of Parion’s epithelial sodium channel (ENaC) inhibitors...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS